PCMA Ad Campaign on Pharmacy Direct and Indirect Remuneration (DIR)
August 14, 2019
We all need to be accountable for helping consumers access safe and affordable prescription drugs while keeping their insurance premiums...
Filter by:
Choose a Topic
Filter by Year:Clear Filters- Research
- Biosimilars
- Drug Abuse Prevention
- Drug Adherence Programs
- Drug Cost Management
- Drug Coupons & Assistance Programs
- Drug Coverage Mandates
- Drug Price Negotiations & Rebates
- Employers, Unions, & Insurers
- FEHB Program
- Formulary Design
- Fraud, Waste, & Abuse
- Generic Drug Utilization
- Health Insurance Marketplace (ACA)
- Home Delivery of Drugs
- Medicaid
- Medicare Part D
- Patient Cost Sharing
- Pharmacy Networks
- Pharmacy Reimbursement & Contracting
- REMS Management
- Specialty Benefit Design
- Specialty Pharmacies
- Specialty Pharmacy Networks
- TRICARE
July 11, 2019
A recent report from the Massachusetts Health Policy Commission used publicly available drug pricing data in an attempt to identify...
May 10, 2019
Recent reports from 46brooklyn Research and their consulting arm 3 Axis Advisors have used publicly available drug pricing data, and...
March 18, 2019
Senior voters with Part D plans have largely not heard about proposed changes to Part D, however, and will punish...
February 26, 2019
Increasing Drug List Prices Show No Correlation with Change in Rebates (2012–2017) View the Infographic Major Findings: Increasing list prices...
Medicare Part B Price Increases
February 25, 2019
See Infographic on prescription drug price increases in Medicare Part B...
Increased Costs Associated With Proposed State Legislation Impacting PBM Tools
January 10, 2019
Visante was commissioned by the Pharmaceutical Care Management Association (PCMA) to estimate the potential cost impact of four types of...
Visante: Reconsidering Drug Prices, Rebates, and PBMs
August 15, 2018
The Visante study highlights top selling Medicare Part D brand-name drugs with steady price increases and no change in rebate...
PCMA Comments on Administration’s Blueprint on Drug Pricing
July 16, 2018
Click here to read PCMA’s comments on the Blueprint...
Oliver Wyman Study: Premium Impact of Removing Manufacturer Rebates from the Medicare Part D Program
July 16, 2018
In 2018, more than 44 million seniors and people with disabilities are expected to be enrolled in Medicare Part D....
Legal Analysis: Antitrust Considerations of Proposals to Limit Rebates
July 15, 2018
A legal analysis raises significant concerns as to drug manufacturers’ ability to offer upfront discounts under current antitrust case law....
National Survey of Seniors Regarding the Medicare Part D Prescription Drug Benefit
July 15, 2018
See topline points from the “National Survey of Seniors Regarding the Medicare Part D Prescription Drug Benefit”...